BioSpaceOriginal article
TScan cuts 75% of workforce while shifting focus to solid tumor program
Negative
AI Analysis
Summary
TScan Therapeutics laid off 75% of its workforce while shifting strategic focus to solid tumor programs and seeking partnerships for its heme and autoimmune programs. The company is advancing two in vivo T cell therapy candidates toward IND-enabling studies.
Importance:5/10
Sentiment:
-0.70
workforce reductionrestructuringfocus shiftin vivo T cell therapystrategic partnershipssolid tumors
Related Companies
Read the original article
Published by BioSpace on September 3, 2026 2:40 PM